AU2023206720A1 - Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids - Google Patents

Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids Download PDF

Info

Publication number
AU2023206720A1
AU2023206720A1 AU2023206720A AU2023206720A AU2023206720A1 AU 2023206720 A1 AU2023206720 A1 AU 2023206720A1 AU 2023206720 A AU2023206720 A AU 2023206720A AU 2023206720 A AU2023206720 A AU 2023206720A AU 2023206720 A1 AU2023206720 A1 AU 2023206720A1
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
acid
ethyl
diethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023206720A
Other languages
English (en)
Inventor
Lina Xu
Chongxi Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TECHFIELDS Inc
Original Assignee
TECHFIELDS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TECHFIELDS Inc filed Critical TECHFIELDS Inc
Publication of AU2023206720A1 publication Critical patent/AU2023206720A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023206720A 2022-01-17 2023-01-12 Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids Pending AU2023206720A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/072270 2022-01-17
CN2022072270 2022-01-17
PCT/CN2023/071973 WO2023134732A1 (en) 2022-01-17 2023-01-12 Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids

Publications (1)

Publication Number Publication Date
AU2023206720A1 true AU2023206720A1 (en) 2024-08-29

Family

ID=87280122

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023206720A Pending AU2023206720A1 (en) 2022-01-17 2023-01-12 Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids

Country Status (10)

Country Link
US (1) US20250099491A1 (https=)
EP (1) EP4465993A4 (https=)
JP (1) JP2025504447A (https=)
KR (1) KR20250005055A (https=)
CN (1) CN118632699A (https=)
AU (1) AU2023206720A1 (https=)
CA (1) CA3252370A1 (https=)
IL (1) IL314290A (https=)
TW (1) TW202339711A (https=)
WO (1) WO2023134732A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118373749A (zh) * 2024-04-29 2024-07-23 四川施成收生态科技有限公司 一种含有2-羟基苯甲酸-2-（二乙氨基）乙酯结构的化合物制备及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH399486A (fr) * 1962-10-02 1965-09-30 Biosedra Lab Procédé de préparation de nouvelles salicylamides
CA2656858C (en) * 2006-07-09 2016-01-19 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetylsalicylic acid
CN101500983B (zh) * 2006-07-26 2015-09-16 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药
CN111012914A (zh) * 2012-01-18 2020-04-17 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
CN112521305B (zh) * 2013-03-15 2023-04-25 苏州泰飞尔医药有限公司 治疗帕金森疾病的新型高穿透力药物及其药物组合物

Also Published As

Publication number Publication date
JP2025504447A (ja) 2025-02-12
US20250099491A1 (en) 2025-03-27
WO2023134732A1 (en) 2023-07-20
TW202339711A (zh) 2023-10-16
EP4465993A4 (en) 2026-01-07
KR20250005055A (ko) 2025-01-09
WO2023134732A9 (en) 2024-08-08
EP4465993A1 (en) 2024-11-27
IL314290A (en) 2024-09-01
CN118632699A (zh) 2024-09-10
CA3252370A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
TWI634888B (zh) 治療帕金森疾病的新穎高穿透性藥物和醫藥組合物
AU2004233587B2 (en) Use of a topical medicament comprising Riluzole
JP6262225B2 (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
EA013973B1 (ru) Способы лечения кожной волчанки при помощи аминоизоиндолиновых соединений
US8337903B2 (en) Antitumoral agents with a benzophenanthridine structure and formulations containing them
JP2013529654A (ja) レボカルニチン及びドベシレートを含む医薬組成物
JP2018507874A (ja) 過剰な体脂肪の治療処置または美容処置のためのｎｋ−３受容体拮抗薬
EP3838887A1 (en) 2-(1-acyloxypentyl) benzoic acid salt formed by basic amino acid or aminoguanidine, preparation method therefor and uses thereof
JP5378221B2 (ja) 非常に高い皮膚浸透率を有するオキシカム及び関連化合物の正荷電水溶性プロドラッグ
TW202128729A (zh) 新肽及其在炎症治療中的用途
WO2023134732A1 (en) Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids
AU2019354771A1 (en) Combination therapy for the treatment of uveal melanoma
ES2237625T3 (es) Uso de un derivado de hidantoina en una composicion farmaceutica contra la hipoalbuminemia.
CN106946866A (zh) 一种预防和治疗脑卒中的药物及其制备方法
KR102857195B1 (ko) (r)-2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물 및 이의 용도
JP7257091B2 (ja) 認知症の治療及び予防薬
JP2024026659A (ja) 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用
US6348488B1 (en) Remedies for motor dysfunction and GAPDH expression inhibitors
CN116549466A (zh) 一种毛蕊花糖苷化合物在制备抗动脉血栓形成的药物中的应用
JP2025527573A (ja) Ｃｄｋ９阻害剤の吸入可能な組成物
JP2025533120A (ja) イミダゾリジニルバニリン酸エーテル誘導体の線維化を伴う疾患の治療における使用
CN120815160A (zh) 一种药物组合物在制备治疗心肌缺血/再灌注损伤药物中的应用
AU2008200878A1 (en) Use of a topical medicament comprising riluzole
WO2008015763A1 (fr) Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire
CN105085479A (zh) 一种新的含氮杂环化合物